WST as reported
West Pharmaceutical Services reported $3.22B of revenue over the trailing twelve months, +11% on the year before. 11 reported series are charted on this page, each one as filed.
$3.22B
Revenue, trailing twelve months · to Q1 2026 · +11% against the twelve months before
- Net Income
- $543M
Net Income · +16% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $458M
Free Cash Flow · +49% year on year · trailing twelve months to Q1 2026
- Op Margin
- 20%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $3.22B | +11% | Q1 2026 |
| Net Income | $543M | +16% | Q1 2026 |
| EPS | $7.48 | +17% | Q1 2026 |
| Gross Margin | 36% | n/a | Q1 2026 |
| Op Margin | 20% | n/a | Q1 2026 |
| Net Margin | 17% | n/a | Q1 2026 |
| ROE | 17% | n/a | Q1 2026 |
| ROA | 12% | n/a | Q1 2026 |
| ROIC | 18% | n/a | Q1 2026 |
| Free Cash Flow | $458M | +49% | Q1 2026 |
| P/E | 46.8 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
West Pharmaceutical Services (WST) - Revenue & ProfitRevenue & ProfitWest Pharmaceutical Services (WST)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Instruments & Supplies
Ranks #4 of 27 by Smart Score